Clinical Trials Browser

Leukemia, Plasma Cell × liposomal doxorubicin × Plasma cell × Clear all

NCT03591744 2018-12-19

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Phase 1 Withdrawn

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell

NCT01328236 2011-09-22

Bortezomib

Phase 2 Unknown

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma